The Immunogenicity Of 7-valent Pneumococcal Conjugate Vaccine In Sick Elderly People For Whom Vaccine Is Not Registered
Funder
National Health and Medical Research Council
Funding Amount
$443,800.00
Summary
The bacteria pneumococcus (also known as streptococcus pneumoniae) is the most common cause of pneumonia in the community, and a major cause of illness and death in the elderly. Rates of antibiotic resistance are also increasing. The pneumococcus is a complex bacteria, with over 80 known serotypes. Most human disease in Australia is caused by 23 of these serotypes. Australia has an ageing population. The health and wellbeing of the elderly has been identified as a national priority. Vaccination ....The bacteria pneumococcus (also known as streptococcus pneumoniae) is the most common cause of pneumonia in the community, and a major cause of illness and death in the elderly. Rates of antibiotic resistance are also increasing. The pneumococcus is a complex bacteria, with over 80 known serotypes. Most human disease in Australia is caused by 23 of these serotypes. Australia has an ageing population. The health and wellbeing of the elderly has been identified as a national priority. Vaccination and prevention of serious infections, a common cause of illness in the elderly, is an achievable public health goal. The National Health and Medical Research Council (NHMRC) of Australia recommends that adults aged 65 years and over should be immunised with 23-valent polysaccharide pneumococcal vaccine (PPV). PPV has been available long term in Australia, but the dilemma associated with its use is that it is least effective in those at greatest risk of pneumococcal disease and its complications, the sick elderly population. A new 7-valent pneumococcal conjugate vaccine (PCV-7) has been available since the end of 2000, but is currently indicated only for children, because it has never been tested in adults. This vaccine uses different technology, and is conjugated to a protein to make it more effective. Clinicals trials of PCV7 have largely been limited to children aged 0-4 years, and have shown it protects 93.9% of children under 2 years of age against invasive pneumococcal disease (IPD). Our study aims to look at the efficacy of this new vaccine, currently only registered for children, in the sub-group of the population who are at highest risk for pneumococcal disease - hospitalised elderly. We will vaccinate hospitalised elderly people with PCV or PPV and compare their immune response to the two different vaccines. If PCV is more effective than PPV, this has implications for the development and use of conjuagated pneumococcal vaccines for adults.Read moreRead less
Enhancing The Efficacy Of Pneumococcal Vaccination Using A Probiotic Adjuvant
Funder
National Health and Medical Research Council
Funding Amount
$302,123.00
Summary
This study will examine the ability of probiotics to enhance the human immune system response of infants immunised with the pneumococcal conjugate vaccine. Probiotics able to improve the immune system would provide greater protection against pneumococcal disease, a major cause of childhood illness and death of Indigenous Australians and among the developing world.
Evaluation Of The Effectiveness Of The 13-valent Pneumococcal Conjugate Vaccine On Pneumococcal Serotypes Causing Pneumonia In Children
Funder
National Health and Medical Research Council
Funding Amount
$1,137,532.00
Summary
Streptococcus pneumonia (Pneumococcus) is a bug that is a leading cause of childhood morbidity and mortality world-wide. Vaccinations have been recently brought onto the national immunisation program to try and combat this. This study aims to assess the new 13 valent Pneumococcal vaccine by studying its effectiveness in preventing childhood pneumonia in Australia by analysing the strains of Pneumococus in the blood and the fluid surrounding the lining the lung in complicated pneumonia using sens ....Streptococcus pneumonia (Pneumococcus) is a bug that is a leading cause of childhood morbidity and mortality world-wide. Vaccinations have been recently brought onto the national immunisation program to try and combat this. This study aims to assess the new 13 valent Pneumococcal vaccine by studying its effectiveness in preventing childhood pneumonia in Australia by analysing the strains of Pneumococus in the blood and the fluid surrounding the lining the lung in complicated pneumonia using sensitive molecular techniques.Read moreRead less
TEXTMEDS – TEXT Messages To Improve MEDication Adherence And Secondary Prevention
Funder
National Health and Medical Research Council
Funding Amount
$1,406,875.00
Summary
TEXTMEDS will evaluate a highly innovative strategy to improve cardiovascular disease secondary prevention using cheap and widely available mobile phone technology. TEXTMEDS is a randomised controlled trial of 1400 patients with acute coronary syndrome that will examine the effect of a semi-personalised secondary prevention support program sent via mobile phone text message on the proportion taking appropriate medications for the secondary prevention of cardiovascular disease and on cardiovascul ....TEXTMEDS will evaluate a highly innovative strategy to improve cardiovascular disease secondary prevention using cheap and widely available mobile phone technology. TEXTMEDS is a randomised controlled trial of 1400 patients with acute coronary syndrome that will examine the effect of a semi-personalised secondary prevention support program sent via mobile phone text message on the proportion taking appropriate medications for the secondary prevention of cardiovascular disease and on cardiovascular risk factors levels (e.g. cholesterol).Read moreRead less
Understanding The Unique Contribution Of Sedentary Behaviour To The Cardio Metabolic Health Of Women
Funder
National Health and Medical Research Council
Funding Amount
$83,149.00
Summary
The risk of heart disease for women increases significantly with the menopause. New evidence suggests that sedentary behaviour (too much sitting as distinct from too little exercise) is also related to heart disease risk. Ms Howard's PhD research will identify whether TV time and other prolonged sitting pose a particular risk for women during and after the menopause. Her studies will identify whether there is a need for women's health recommendations on reducing sitting time.
Accurate Prediction Of Individual Risk To Disease From Genome-wide Association Studies
Funder
National Health and Medical Research Council
Funding Amount
$269,371.00
Summary
Risk for many complex diseases (such as psychiatric disorders or heart disease) has a substantial genetic component, however few specific high risk variants have been identified. Evidence is mounting that there are likely to be hundreds of risk loci each individually conferring a very low increase in relative risk for disease. We aim to develop methods that utilise information from multiple genetic risk variants simultaneously to create a 'genomic profile' of risk.
A Longitudinal Investigation Of The Efficacy Of Pharmacological Smoking Cessation Aids In Real-life Settings
Funder
National Health and Medical Research Council
Funding Amount
$592,837.00
Summary
Currently around 3 million Australians, or 17% of people aged 14 years and over, smoke tobacco daily. These smokers are at major risk of developing coronary heart disease, stroke, peripheral vascular disease, and a variety of cancers, including lung, laryngeal, oral, kidney, bladder, breast, pancreas and colon cancers. At any one time almost half of Australian smokers intend to quit smoking or have already set a date to do so but few (around 10%) succeed on each attempt. Clinical trials of quitt ....Currently around 3 million Australians, or 17% of people aged 14 years and over, smoke tobacco daily. These smokers are at major risk of developing coronary heart disease, stroke, peripheral vascular disease, and a variety of cancers, including lung, laryngeal, oral, kidney, bladder, breast, pancreas and colon cancers. At any one time almost half of Australian smokers intend to quit smoking or have already set a date to do so but few (around 10%) succeed on each attempt. Clinical trials of quitting aids, such as nicotine patches, gum and Zyban, suggest that smokers are around twice as likely to quit if using these. However clinical trials are conducted in artificial environments and these quitting aids appear to have a far smaller impact on successful quitting rates in the 'real world'. Pharmaceutical quitting aids are heavily advertised by drug companies and widely used in Australia. Futhermore the Commonwealth Government has invested over $133 million dollars subsidising such aids to Australian smokers in the past four years. However it is not known to what extent these quitting aids have made a difference to Australian smoking rates. Sales volumes of pharmaceutical quitting aids appear not to have translated into expected increases in numbers of smokers successfully quitting, suggesting they are less effective than clinical trials suggest. The present study aims to investigate whether pharmaceutical quitting aids actually are less effective in the 'real world', and if so, why.Read moreRead less
Development Of Contemporary Surveillance And Control Methodologies For Dengue And Other Mosquito-borne Viral Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$512,290.00
Summary
This research proposal will address the need for better surveillance and control methodologies for mosquito-borne viral diseases and their vectors, including dengue and its global mosquito vector, Ae. aegypti, and a range of other important arboviral diseases throughout Australia. Research will focus in three areas: surveillance and control of Ross River and Barmah Forest viruses; development of contemporary risk management frameworks for dengue; and innovative investigations of insect age to pr ....This research proposal will address the need for better surveillance and control methodologies for mosquito-borne viral diseases and their vectors, including dengue and its global mosquito vector, Ae. aegypti, and a range of other important arboviral diseases throughout Australia. Research will focus in three areas: surveillance and control of Ross River and Barmah Forest viruses; development of contemporary risk management frameworks for dengue; and innovative investigations of insect age to provide evidence based monitoring and novel approaches to arbovirus disease prevention.Read moreRead less
Retinal Microvascular Signs In Angina And Coronary Artery Disease: The Australian Heart Eye Study (AHES)
Funder
National Health and Medical Research Council
Funding Amount
$631,223.00
Summary
The Australian Heart Eye Study will determine whether vessel signs from the retina at the back of the eye are an independent marker of heart disease as assessed by a coronary angiogram. New imaging techniques permit a rapid assessment of these signs. This project could lead to the development of an innovative, non-invasive test that could be used to screen people for the risk of coronary heart disease, in addition to traditional risk factors like blood pressure, smoking, cholesterol and obesity.
Optimising Primary Care Risk Profiling And Management Of Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$408,387.00
Summary
Dr Carrington's CDF will support her career progression in 4 areas of translational research: 1. Closing the gap in ATSI heart health – optimising management of heart disease in Central Australia 2. Supporting healthy regional communities - developing cost-effective risk reduction clinics 3. Coordinating the care of complex cardiac conditions – refining an electronic tool to optimise GP management 4. International heart health – develop an effective primary care model of risk reduction in Sub-Sa ....Dr Carrington's CDF will support her career progression in 4 areas of translational research: 1. Closing the gap in ATSI heart health – optimising management of heart disease in Central Australia 2. Supporting healthy regional communities - developing cost-effective risk reduction clinics 3. Coordinating the care of complex cardiac conditions – refining an electronic tool to optimise GP management 4. International heart health – develop an effective primary care model of risk reduction in Sub-Saharan AfricaRead moreRead less